UK-CAB 35 – Early diagnosis and primary infection
Friday 9 July 2010
At the MRC Clinical Trials Unit, 222 Euston Road, London, NW1
| 09:30–10:00 | Registration, refreshments and expenses |
| 10:00–10:05 | Welcome and UK-CAB updates |
| 10:05–10.30 | Pre-meeting for Merck – Simon Collins |
| 10:30–11:15 | Early diagnosis and primary infection – Prof Jonathan Weber, Faculty of Medicine at Imperial College London |
| 11:00–11:15 | Break |
| 11.15–12.00 | CASCADE study: Seroconverters Database – Kholoud Porter |
| 12.00–12.30 | Vienna preview: a guide on what to look out for; podcasts, updates from organisations, the 1st time IAC attendee – Paul Clift and Silvia Petretti |
| 12:30–14:00 | Lunch |
| 14:00–15:30 | Company meeting: Merk |
| 15.30–15.35 | Break |
| 15:35–16.00 | BHIVA feedback, UKCAB AOB |
| 16.00 | Close |
Background reading
Bruce Walker abstract:
Immune Control in Chronic Human Viral Infections
http://www.hhmi.org/research/investigators/walkerbd.html
Treatment in primary HIV infection
http://i-base.info/htb/5669
Primary Infection
http://www.aidsmap.com/cms1044761.aspx
Primary HIV Infection: to treat or not to treat?
Download pdf file [196 Kb]
NOTE: This is a longer and more technical report, but very interesting. One of the authors, Prof Jonathan Weber will be speaking at the meeting. The three articles above summarize this document.
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.
The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.